ClinicalTrials.gg
CompletedNCT07016412Updated Sep 11, 2026

Clinical Study of Ensifentrine-Glycopyrrolate (MK-5884A/RPL554) Fixed-dose Combination Dose Ranging in Participants With COPD (MK-5884A-029/RPL554-CO-212)

A Phase 2 interventional study of Ensifentrine 3 mg and Glycopyrrolate 21.25 mcg in Chronic Obstructive Pulmonary Disease, sponsored by Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA. Completed at 57 sites in United States. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-11.

Sponsored by Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
497
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing ensifentrine in Pulmonary Disease, Chronic Obstructive — 1 open to participants now, 2 under way, 1 of them phase 3. ensifentrine · Pulmonary Disease, Chronic Obstructive.

Enrollment
5th of 15
497 · median 79
Started
2025
with 1 other
Phase 2
8 of 15
none open now
Registered
13th of 15
by date
Lead sponsor
3 of 15
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA

Among the 15 studies testing ensifentrine in Pulmonary Disease, Chronic Obstructive, this one is the 5th largest by enrollment, is one of 2 that started in 2025, is one of 8 in phase 2, and was the 13th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

1 of the 15 studies testing ensifentrine in Pulmonary Disease, Chronic Obstructive is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About ensifentrine

ensifentrine: first FDA approval 2024 (OHTUVAYRE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing ensifentrine in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

This study will assess the safety and efficacy of fixed dose combinations of ensifentrine with two different glycopyrrolate dose levels compared to placebo and to the individual components of the fixed dose combinations, each administered twice a day via standard jet nebulizer, in adult participants with chronic obstructive pulmonary disease (COPD).

Read the detailed description

Enrolled participants will be expected to participate for approximately 7 weeks: 1 to 2 weeks for screening, 4 weeks of treatment, and 1 week of follow up. Participants will be randomized to one of 6 treatment arms: two fixed dose combinations of ensifentrine (3 mg) and glycopyrrolate (either 21.25 or 42.5 mcg), the 3 individual components as monotherapies, or placebo. All treatments will be administered twice a day via oral inhalation by a standard jet nebulizer. The primary objective of this study is to evaluate the bronchodilator effects of the fixed dose combinations compared to each of the individual components and to placebo.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease

Keywords

  • Chronic Obstructive Pulmonary Disease
  • COPD
  • bronchodilator
  • ensifentrine-glycopyrrolate
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males are eligible to participate if they agree to use or abstinence, and refrain from donating fresh unwashed semen during the study and for at least 30 days post-study
  • Females are eligible to participate if they are not pregnant, breastfeeding and if one of the following conditions apply:

    1. Not a woman of OR
    2. Agrees to follow the contraceptive guidance from screening throughout the study and for at least 30 days post-study
    3. Agrees not to donate eggs for the purpose of reproduction from screening throughout the study and for at least 30 days post-study
  • Current of former cigarette smokers with a history of smoking ≥ 10 pack years at the time of signing [number of pack years = (number of cigarettes per day / 20) × number of years smoked (e.g., 20 cigarettes per day for 10 years, or 10 cigarettes per day for 20 years)]. Pipe and/or cigar use cannot be used to calculate pack-year history. Former smokers are defined as those who have stopped smoking for at least 6 months prior to signing informed consent. Smoking cessation programs are permitted during the study
  • Participants with an established clinical history of as defined by the American Thoracic Society (ATS)/European Respiratory Society (ERS) guidelines with symptoms compatible with COPD
  • A score of ≥ 2 on the Modified Medical Research Council (mMRC) Dyspnea Scale at the Screening Visit
  • Post-bronchodilator (4 puffs of albuterol) spirometry during the Screening Period demonstrating both the following:

    1. /forced vital capacity (FVC) ratio of \< 0.70 AND
    2. FEV1 ≥ 30 % and ≤ 70% of predicted normal
  • A posterior-anterior chest x-ray (CXR) during the Screening Period or within 12 months of signing the Informed Consent Form (ICF) showing no abnormalities unrelated to COPD. If a CXR within the past 12 months is not available but a computed tomography (CT) scan within the same time period is available, the CT scan may be reviewed in place of a CXR
  • Participants on no maintenance/background therapy or participants on stable maintenance as either long-acting β2-agonist (LABA) or long-acting β2-agonist/Inhaled (LABA/ICS) therapy are eligible. Subjects taking maintenance therapy must demonstrate regular use of maintenance therapy, in any form, for at least 60 days prior to signing informed consent and agree to continue use of their current permitted LABA or LABA/ICS medication for the duration of the screening and treatment period
  • Capable of withholding from short-acting bronchodilators for 4 hours prior to spirometry testing. Participants receiving maintenance therapy with a LABA or LABA/ICS must be capable of withholding twice-daily maintenance therapy for 24 hours and once-daily maintenance therapy for 48 hours prior to initiation of any spirometry
  • Capable of using the study jet nebulizer correctly
  • Ability to perform acceptable spirometry in accordance with ATS/ERS guidelines
  • Willing and able to attend all study visits and adhere to all study assessments and procedures

Exclusion criteria

Exclusion Criteria:

  • Concomitant pulmonary disease other than (i.e., asthma, tuberculosis, lung cancer, bronchiectasis, sarcoidosis, lung fibrosis, interstitial lung diseases, sleep apnea (unless controlled with stable continuous positive airway pressure [CPAP] use), known alpha-1 antitrypsin deficiency, core pulmonale or other non-specific pulmonary disease
  • Within 6 months prior to randomization, a COPD exacerbation requiring hospitalization
  • Within 3 months prior to randomization, use of oral or systemic therapies for COPD exacerbations (for example, oral, intravenous, or intramuscular , antibiotics, theophylline, and roflumilast)
  • History of life-threatening COPD, including Intensive Care Unit admission and/or requiring intubation
  • Severe comorbidities including

    1. unstable cardiac disease (myocardial infarction within 1 year prior to randomization, unstable angina within 6 months prior to randomization, unstable or life-threatening arrhythmia requiring intervention within 3 months prior to randomization, diagnosis of (NYHA) class III or IV heart disease, or
    2. any other clinically significant medical conditions including uncontrolled diseases (e.g., endocrine, neurological, hepatic, gastrointestinal, renal, hematological, urological, immunological, psychiatric [e.g. untreated significant depression, anxiety or history of suicidality], or ophthalmic diseases) that would, in the opinion of the Investigator, preclude the participant from safely completing the required tests or the study, or is likely to result in disease progression that would require withdrawal of the participant
  • History of or clinically significant on-going bladder outflow obstruction or history of catheterization for relief of bladder outflow obstruction within 6 months prior to randomization
  • History of narrow angle glaucoma
  • History of or intolerance to aerosol medications, albuterol, ensifentrine, or glycopyrrolate or any of its /components, anticholinergic agents, or sympathomimetic amines
  • History of or current of any organ system, treated or untreated within the 5 years prior to randomization, except for localized basal or squamous cell carcinoma of the skin
  • Other significant psychiatric disease that would likely result in the participant not being able to complete the study, in the opinion of the Investigator
  • Findings on physical examination that an investigator considers to be clinically significant or abnormal during the Screening Period including hematology, biochemistry, viral serology, and
  • Prior or current use of Ohtuvayre (ensifentrine)
  • Previous lung resection or lung reduction surgery within 1-year of randomization
  • Long term oxygen use defined as oxygen therapy prescribed for greater than 12 hours per day. As needed oxygen use (≤ 12 hours per day) is not exclusionary
  • Pulmonary rehabilitation unless such treatment has been stable from 4 weeks prior to signing the ICF and plans to remain stable during the study. Pulmonary rehabilitation programs should not be started or completed during participation in the study
  • Major surgery (requiring general anesthesia) in the 6 weeks prior randomization, lack of full recovery from surgery at randomization, or planned surgery through the end of the study
  • Current or history of drug or alcohol abuse within the 5 years prior to randomization
  • Estimated (eGFR) \< 30 mL/min as tested during the Screening Period
  • (ALT) ≥ 2 × (ULN), aspartate aminotransferase (AST) ≥ 2 × ULN, alkaline phosphatase and/or total > 1.5 × ULN (participants with Gilbert's syndrome can be included with total bilirubin >1.5 × ULN as long as direct bilirubin is ≤ 1.5 × ULN)
  • Use of an experimental drug within 30 days or 5 half-lives of signing the ICF, whichever is longer, and/or participation in a study treatment-free follow-up phase of a clinical study within 30 days prior to signing the ICF
  • Use of an experimental medical device or participation in a follow-up phase of an experimental medical device clinical study within 30 days prior to
  • Affiliation with the investigator site, including an Investigator, Sub-Investigator, study coordinator, study nurse, other employee of participating investigator or study site or a family member of the aforementioned
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
497 participants (actual)

Study arms

  • Experimental
    Treatment Arm A: Ensifentrine plus Glycopyrrolate

    Participants will receive ensifentrine 3 mg / glycopyrrolate 42.5 mcg twice a day for up to 28 days via oral inhalation by a standard jet nebulizer.

    Drug: Ensifentrine 3 mg · Drug: Glycopyrrolate 42.5 mcg

  • Experimental
    Treatment Arm B: Ensifentrine plus Glycopyrrolate

    Participants will receive ensifentrine 3 mg / glycopyrrolate 21.25 mcg twice a day for up to 28 days via oral inhalation by a standard jet nebulizer.

    Drug: Ensifentrine 3 mg · Drug: Glycopyrrolate 21.25 mcg

  • Active comparator
    Treatment Arm C: Glycopyrrolate

    Participants will receive glycopyrrolate monotherapy 42.5 mcg twice a day for up to 28 days via oral inhalation by a standard jet nebulizer.

    Drug: Glycopyrrolate 42.5 mcg

  • Active comparator
    Treatment Arm D: Glycopyrrolate

    Participants will receive glycopyrrolate monotherapy 21.25 mcg twice a day for up to 28 days via oral inhalation by a standard jet nebulizer.

    Drug: Glycopyrrolate 21.25 mcg

  • Active comparator
    Treatment Arm E: Ensifentrine

    Participants will receive ensifentrine monotherapy 3 mg twice a day for up to 28 days via oral inhalation by a standard jet nebulizer.

    Drug: Ensifentrine 3 mg

  • Placebo comparator
    Treatment Arm F: Placebo

    Participants will receive placebo twice a day for up to 28 days via oral inhalation by a standard jet nebulizer.

    Drug: Placebo

Interventions

  • Administered by a standard jet nebulizer, twice daily for 28 consecutive days

  • Administered by a standard jet nebulizer, twice daily for 28 consecutive days

  • Administered by a standard jet nebulizer, twice daily for 28 consecutive days

  • DrugPlacebo

    Administered by a standard jet nebulizer, twice daily for 28 consecutive days

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Average Forced Expiry Volume in 1 Second (FEV1) Area Under the Curve Versus Time From Time 0 to 4 Hours (AUC0-4h)

    Spirometry will be performed to determine the FEV1. Change from baseline in average FEV1 area under the curve from 0 to 4 hours on Day 28 will be reported.

    Time frame: Baseline and Day 28

Secondary outcomes

  1. Change From Baseline in Peak FEV1 Measured Over 4 Hours Post-Dose

    Spirometry will be performed to determine the FEV1. Change from baseline in peak FEV1 over 4 hours following dosing on Day 28 will be reported.

    Time frame: Baseline and Day 28

  2. Change From Baseline in Average FEV1 Area Under the Curve Versus Time From Time 0 to 12 Hours (AUC0-12h)

    Spirometry will be performed to determine the FEV1. Change from baseline in average FEV1 area under the curve from 0 to 12 hours on Day 28 will be reported.

    Time frame: Baseline and Day 28

  3. Change From Baseline in Morning Trough FEV1 on Day 29

    Spirometry will be performed to determine the FEV1. Change from baseline in morning trough FEV1 measured on Day 29 will be reported.

    Time frame: Baseline and Day 29

  4. Change From Baseline in Evening Trough FEV1 on Day 28

    Spirometry will be performed to determine the FEV1. Change from baseline in evening trough FEV1 measured on Day 28 will be reported.

    Time frame: Baseline and Day 28

  5. Change From Baseline in Morning Trough FEV1 on Day 28

    Spirometry will be performed to determine the FEV1. Change from baseline in morning trough FEV1 measured on Day 28 will be reported.

    Time frame: Baseline and Day 28

  6. Change From Baseline in Average FEV1 AUC0-4h Measured After First Dose on Day 14

    Spirometry will be performed to determine the FEV1. Change from baseline in average FEV1 area under the curve from 0 to 4 hours following the first dose on Day 14 will be reported.

    Time frame: Baseline and Day 14

  7. Change From Baseline in Peak FEV1 Measured Over 4 Hours After First Dose on Day 14

    Spirometry will be performed to determine the FEV1. Change from baseline in peak FEV1 over 4 hours following the first dose on Day 14 will be reported.

    Time frame: Baseline and Day 14

  8. Change From Baseline in Average FEV1 AUC0-4h Measured After First Dose on Day 1

    Spirometry will be performed to determine the FEV1. Change from baseline in average FEV1 area under the curve from 0 to 4 hours following the first dose on Day 1 will be reported.

    Time frame: Baseline and Day 1

  9. Change from Baseline in Peak FEV1 Measured Over 4 Hours After First Dose on Day 1

    Spirometry will be performed to determine the FEV1. Change from baseline in peak FEV1 over 4 hours following the first dose on Day 1 will be reported.

    Time frame: Baseline and Day 1

  10. Change in Symptoms of Dyspnea from Baseline as Measured by Transition Dyspnea Index (TDI) Score on Day 14

    The TDI measures the change in dyspnea symptom severity from the baseline as measured by the Baseline Dyspnea Index (BDI). It is based on three components, functional impairment, magnitude of task, and magnitude of effort, that evoke dyspnea in activities of daily living. The BDI score ranges from 0 (very severe impairment) to 4 (no impairment) for each domain and are summed to determine the BDI focal score (0-12). The TDI score ranges from -3 (major deterioration) to +3 (major improvement) for each domain. The sum of all domains yields the TDI focal score (-9 to +9). Change from baseline in TDI score on Day 14 will be reported.

    Time frame: Baseline and Day 14

  11. Change in Symptoms of Dyspnea from Baseline as Measured by TDI Score on Day 28

    The TDI measures the change in dyspnea symptom severity from the baseline as measured by the BDI. It is based on three components, functional impairment, magnitude of task, and magnitude of effort, that evoke dyspnea in activities of daily living. The BDI score ranges from 0 (very severe impairment) to 4 (no impairment) for each domain and are summed to determine the BDI focal score (0-12). The TDI score ranges from -3 (major deterioration) to +3 (major improvement) for each domain. The sum of all domains yields the TDI focal score (-9 to +9). Change from baseline in TDI score on Day 28 will be reported.

    Time frame: Baseline and Day 28

  12. Change From Baseline in Health-Related Quality of Life as Measured by Saint George's Respiratory Questionnaire (SGRQ) Total Score

    The SGRQ Patient Reported Outcome (PRO) measure is a 50- item questionnaire designed to assess health-related quality of life in patients with COPD in terms of symptoms, daily activity limitation, and psychosocial well-being. The total score ranges from 0 to 100, with lower scores indicating better health status. Change from baseline in health-related quality of life as assessed using SGRQ total score on Day 28 will be reported.

    Time frame: Baseline and Day 28

  13. Number of Participants who Experience at Least one Treatment Emergent Adverse Event (TEAE)

    An AE is any untoward medical occurrence in a subject, temporally associated with the use of the study medication, whether or not considered related to the study medication. Number of participants who experience at least one TEAE will be reported.

    Time frame: Up to approximately 5 weeks

  14. Number of Participants With Markedly Abnormal Changes in Hematology Parameters

    Number of participants with markedly abnormal changes in hematology parameters will be reported.

    Time frame: Up to approximately Day 28

  15. Number of Participants With Markedly Abnormal Changes in Blood Chemistry Parameters

    Number of participants with markedly abnormal changes in blood chemistry parameters will be reported.

    Time frame: Up to approximately Day 28

  16. Number of Participants With Markedly Abnormal Changes in QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)

    Number of participants with markedly abnormal changes in QTcF measurements will be reported.

    Time frame: Up to approximately Day 28

  17. Number of Participants With Markedly Abnormal Changes in Heart Rate

    Number of participants with markedly abnormal changes in heart rate will be reported.

    Time frame: Up to approximately Day 28

  18. Number of Participants With Markedly Abnormal Changes in Blood Pressure

    Number of participants with markedly abnormal changes in blood pressure will be reported.

    Time frame: Up to approximately Day 28

  19. Number of Participants With Markedly Abnormal Changes in Pulse Rate

    Number of participants with markedly abnormal changes in pulse rate will be reported.

    Time frame: Up to approximately Day 28

  20. Area Under the Concentration-Time Curve from Time 0 to 12 Hours (AUC0-12hrs) of Ensifentrine

    Blood samples will be collected to determine the AUC0-12hrs of ensifentrine.

    Time frame: Predose and at designated timepoints up to 12 hours postdose

  21. Maximum Plasma Concentration (Cmax) of Ensifentrine

    Blood samples will be collected to determine the Cmax of ensifentrine.

    Time frame: Predose and at designated timepoints up to day 28 postdose

  22. Plasma Trough Concentration (Ctrough) of Ensifentrine

    Blood samples will be collected to determine the Ctrough of ensifentrine.

    Time frame: Day 28

  23. Average Plasma Concentrations (Cavg) of Ensifentrine

    Blood samples will be collected to determine the Cavg of ensifentrine.

    Time frame: Day 28

  24. Time to Maximum Plasma Concentration (Tmax) of Ensifentrine

    Blood samples will be collected to determine the Tmax of ensifentrine.

    Time frame: Predose and at designated timepoints up to day 28 postdose

  25. Apparent Clearance (CL/F) of Ensifentrine

    Blood samples will be collected to determine the CL/F of ensifentrine.

    Time frame: Day 28

  26. Accumulation Ratio Cmax (ARCmax) of Ensifentrine

    Blood samples will be collected to determine the ARCmax of ensifentrine.

    Time frame: Predose and at designated timepoints up to day 28 postdose

  27. Accumulation Ratio AUC (ARAUCs) of Ensifentrine

    Blood Samples Will be Collected to Determine the ARAUC of Ensifentrine.

    Time frame: Predose and at designated timepoints up to day 28 postdose

  28. Area Under the Concentration-Time Curve from Time 0 to 12 Hours (AUC0-12hrs) of Glycopyrronium

    Blood samples will be collected to determine the AUC0-12hrs of glycopyrronium.

    Time frame: Predose and at designated timepoints up to 12 hours postdose

  29. Maximum Plasma Concentration (Cmax) of Glycopyrronium

    Blood samples will be collected to determine the Cmax of glycopyrronium.

    Time frame: Predose and at designated timepoints up to day 28 postdose

  30. Plasma Trough Concentration (Ctrough) of Glycopyrronium

    Blood samples will be collected to determine the Ctrough of glycopyrronium.

    Time frame: Day 28

  31. Average Plasma Concentrations (Cavg) of Glycopyrronium

    Blood samples will be collected to determine the Cavg of glycopyrronium.

    Time frame: Day 28

  32. Time to Maximum Plasma Concentration (Tmax) of Glycopyrronium

    Blood samples will be collected to determine the Tmax of glycopyrronium.

    Time frame: Predose and at designated timepoints up to day 28 postdose

  33. Apparent Clearance (CL/F) of Glycopyrronium

    Blood samples will be collected to determine the CL/F of glycopyrronium.

    Time frame: Day 28

  34. Accumulation Ratio Cmax (ARCmax) of Glycopyrronium

    Blood samples will be collected to determine the ARCmax of glycopyrronium.

    Time frame: Predose and at designated timepoints up to day 28 postdose

  35. Accumulation Ratio AUC (ARAUCs) of Glycopyrronium

    Blood Samples Will be Collected to Determine the ARAUC of glycopyrronium.

    Time frame: Predose and at designated timepoints up to day 28 postdose

07

Study locations

57 sites
  • SEC Clinical Research, LLC
    Dothan, Alabama 36305-7375, United States
  • Elite Clinical Studies, LLC
    Phoenix, Arizona 85018, United States
  • Tucson Clinical Research Institute
    Tucson, Arizona 85712, United States
  • Downtown LA Research Center Inc - ClinEdge
    Los Angeles, California 90017, United States
  • California Medical Research Associates, Inc.
    Northridge, California 91324-6200, United States
  • Northern California Research Corp
    Sacramento, California 95821-2640, United States
  • Clinical Research of West Florida Inc
    Clearwater, Florida 33765, United States
  • Fleming Island Center For Clinical Research
    Fleming Island, Florida 32003, United States
  • Florida Institute For Clinical Research LLC
    Orlando, Florida 32825-4454, United States
  • Ormond Beach Clinical Research
    Ormond Beach, Florida 32174-8196, United States
  • Progressive Medical Research
    Port Orange, Florida 32127-5169, United States
  • Clinical Research of West Florida Inc - Tampa
    Tampa, Florida 33606, United States
  • Centricity Research Columbus Georgia Multispecialty - PPDS
    Columbus, Georgia 31904, United States
  • ASHA Clinical Research - Hammond
    Hammond, Indiana 46324, United States
  • Velocity Clinical Research - Valparaiso
    Valparaiso, Indiana 46383, United States
  • Velocity Clinical Research (Rockville - Maryland) - PPDS
    Rockville, Maryland 20854-2960, United States
  • Revive Research Institute, Inc
    Southfield, Michigan 48075, United States
  • Clinical Research Institute, Inc - CRN
    Plymouth, Minnesota 55441-2676, United States
  • Midwest Chest Consultants PC
    Saint Charles, Missouri 63301, United States
  • Midwest Clinical Research LLC
    St Louis, Missouri 63141-7051, United States
  • The Clinical Research Center LLC - CRN
    St Louis, Missouri 63141, United States
  • Sierra Clinical Research
    Las Vegas, Nevada 89106, United States
  • Trialfinity Clinical Research Center
    Hamilton, New Jersey 08619, United States
  • Horizon Family Medical Group - New Windsor Primary Care
    New Windsor, New York 12553-7754, United States
  • American Health Research Inc
    Charlotte, North Carolina 28277, United States
  • Clinical Research of Gastonia
    Gastonia, North Carolina 28054-7481, United States
  • Stern Research Partners, LLC
    Huntersville, North Carolina 28078, United States
  • Monroe Biomedical Research -343 Venus St
    Monroe, North Carolina 28112-4025, United States
  • Carolina Research Center, Inc
    Shelby, North Carolina 28150-3803, United States
  • Bernstein Clinical Research Center Inc
    Cincinnati, Ohio 45231-4927, United States
  • Remington Davis Clinical Research
    Columbus, Ohio 43215, United States
  • Advance Clinical Research
    Kettering, Ohio 45439, United States
  • Clinical Research Associates of Central PA
    DuBois, Pennsylvania 15801-2277, United States
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15213, United States
  • Velocity Clinical Research - Anderson - PPDS
    Anderson, South Carolina 29621-4822, United States
  • Pharmacorp Clinical Trials Incorporated
    Charleston, South Carolina 29412, United States
  • Piedmont Research Partners LLC
    Fort Mill, South Carolina 29707-4514, United States
  • Velocity Clinical Research - Gaffney - PPDS
    Gaffney, South Carolina 29340-4737, United States
  • Lowcountry Lung and Critical Care PA
    North Charleston, South Carolina 29406, United States
  • Monroe Biomedical Research Charleston
    North Charleston, South Carolina 29406, United States
  • Clinical Research of Rock Hill
    Rock Hill, South Carolina 29732, United States
  • Spartanburg Medical Research
    Spartanburg, South Carolina 29303-4755, United States
  • Velocity Clinical Research
    Spartanburg, South Carolina 29303, United States
  • Velocity Clinical Research - Union - PPDS
    Union, South Carolina 29379, United States
  • Chattanooga Research & Medicine, PLLC
    Chattanooga, Tennessee 37404, United States
  • ClinSearch - Chattanooga
    Chattanooga, Tennessee 37421, United States
  • Clinical Trials Center of Middle Tennessee
    Franklin, Tennessee 37067-5665, United States
  • MultiSpecialty Clinical Research, Inc
    Johnson City, Tennessee 37604, United States
  • Inquest Clinical Research
    Baytown, Texas 77521, United States
  • Corsicana Medical Research
    Corsicana, Texas 75110-2471, United States
  • Horizon CR: Houston Pulmonary Sleep & Allergy Associates - Cypress - ClinEdge - PPDS
    Cypress, Texas 77429, United States
  • Greater Heights Memorial Pulmonary and Sleep
    Houston, Texas 77008, United States
  • Houston Pulmonary Medicine Associates, PA - Biopharma Informatic - PPDS
    Houston, Texas 77089, United States
  • Huntsville Research Institute LLC
    Huntsville, Texas 77340, United States
  • Element Research Group
    San Antonio, Texas 78258, United States
  • Sherman Clinical Research - 403 N. Highland Ave
    Sherman, Texas 75092, United States
  • Tranquil Clinical Research
    Webster, Texas 77598-4085, United States
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2025 to primary completion in Aug 2026, 12 months.

Of 118 industry-sponsored phase 2 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 20. This study's 12 months is below that.

Counting every sponsor, half of 165 studies reached it within 17 months; a quarter within 10 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2025
First posted
Jun 11, 2025
StartActual
Jul 31, 2025
Primary completionActual
Aug 17, 2026
CompletionActual
Aug 17, 2026
Last update
Sep 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07016412
Responsible party
Sponsor
First posted
Jun 11, 2025
Start date
Jul 31, 2025
Primary completion
Aug 17, 2026
Completion
Aug 17, 2026
Last update
Sep 11, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ensifentrine · Glycopyrrolate

Start the discussion